Literature DB >> 8383862

Induction of the expression of the interleukin-1 beta gene in mouse spleen by ionizing radiation.

H Ishihara1, K Tsuneoka, A B Dimchev, M Shikita.   

Abstract

Spleen cells freshly isolated from normal mice were irradiated with 20 Gy X rays in culture. Northern blot hybridizations revealed that expression of the interleukin-1 beta (IL-1 beta) gene was induced immediately after irradiation and was increased for 2 h thereafter. Dibutyryl cyclic AMP also caused a persistent expression of the IL-1 beta gene, although it differed from X rays in that it coincidentally induced expression of the c-fos gene, which was not induced by X rays. Activation of either protein kinase C or calmodulin also induced early expression of both IL-1 beta and c-fos. Myeloid cells collected from the spleen of mice with granulocytic leukemia were X-irradiated in culture as above. The leukemia cells responded to X rays as well as to other stimuli in the same manner as the spleen cells, except that IL-1 beta mRNA was no longer detected 30 min after irradiation while c-fos was detectable for 2 h. When the leukemia cells were irradiated twice with a 3-h interval between irradiations, the second irradiation led to prolonged expression of IL-1 beta without inducing c-fos expression. These results suggest that ionizing radiation elicits early expression of the IL-1 beta gene through a mechanism that does not involve protein kinase C or A, or the transcription factor, c-fos. Whole-body irradiation of mice with 50 Gy 137Cs gamma rays also induced IL-1 beta expression in spleen but not in bone marrow or liver, although there was a delay of several hours before it was amply expressed. Furthermore, a delay as long as 24 or 72 h was observed when the radiation dose was reduced to 8.5 or 4 Gy. The results of this in vivo study suggest that the rapidity of expression of the IL-1 beta gene is dependent on the dose of radiation, and that the cells in the body cannot respond to radiation as rapidly as cells in culture.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383862

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  17 in total

Review 1.  Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment.

Authors:  Andrew B Sharabi; Phuoc T Tran; Michael Lim; Charles G Drake; Theodore L Deweese
Journal:  Oncology (Williston Park)       Date:  2015-05       Impact factor: 2.990

Review 2.  Effects of irradiation on tumor cell survival, invasion and angiogenesis.

Authors:  Odysseas Kargiotis; Aliki Geka; Jasti S Rao; Athanasios P Kyritsis
Journal:  J Neurooncol       Date:  2010-05-07       Impact factor: 4.130

Review 3.  Chapter seven--Cancer treatment with gene therapy and radiation therapy.

Authors:  Sergey A Kaliberov; Donald J Buchsbaum
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

Review 4.  Combining radiotherapy and cancer immunotherapy: a paradigm shift.

Authors:  Silvia C Formenti; Sandra Demaria
Journal:  J Natl Cancer Inst       Date:  2013-01-04       Impact factor: 13.506

Review 5.  Combining radiotherapy and immunotherapy: a revived partnership.

Authors:  Sandra Demaria; Nina Bhardwaj; William H McBride; Silvia C Formenti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-11-01       Impact factor: 7.038

6.  Occupational levels of radiation exposure induce surface expression of interleukin-2 receptors in stimulated human peripheral blood lymphocytes.

Authors:  Y Xu; C L Greenstock; A Trivedi; R E Mitchel
Journal:  Radiat Environ Biophys       Date:  1996-05       Impact factor: 1.925

7.  Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line.

Authors:  Jennifer J Parker; Jennifer C Jones; Samuel Strober; Susan J Knox
Journal:  Clin Immunol       Date:  2013-03-26       Impact factor: 3.969

8.  In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer.

Authors:  Anna R Kwilas; Renee N Donahue; Michael B Bernstein; James W Hodge
Journal:  Front Oncol       Date:  2012-09-06       Impact factor: 6.244

9.  Radiation as an immunological adjuvant: current evidence on dose and fractionation.

Authors:  Sandra Demaria; Silvia C Formenti
Journal:  Front Oncol       Date:  2012-10-26       Impact factor: 6.244

10.  Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.

Authors:  Laura Ridolfi; Francesco de Rosa; Ruggero Ridolfi; Giorgia Gentili; Linda Valmorri; Emanuela Scarpi; Elisabetta Parisi; Antonino Romeo; Massimo Guidoboni
Journal:  J Transl Med       Date:  2014-09-23       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.